Imricor Medical Systems, Inc. announced that it has received AUD 2.861607 million in funding
days prior to closing, with no discount applied. The Class A Common Stock issued to US investors, and also upon exercise of the warrant, are subject to a 12-month holding period. The transaction included participation from US investors and New Zealand investors. US investors also received 10-year warrants to purchase a total of 384,616
additional shares of Class A Common Stock and New Zealand investors also received 10-year warrants to purchase a total of 319,068 additional CDIs at AUD 1 per CDI.